Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Stem Cell Usage

Comparison of outcomes after transplantation of peripheral blood stem cells versus bone marrow following an identical nonmyeloablative conditioning regimen

Bone Marrow Transplantation volume 40, pages 19–27 (2007)Cite this article

Abstract

This is the first study to examine the outcomes in 54 patients with hematologic malignancies who received an HLA-matched related donor bone marrow (BM, n=42) or GCSF-mobilized peripheral blood stem cells (PBSC, n=12) following identical nonmyeloablative conditioning with the intention of induction of mixed chimerism (MC) followed by prophylactic donor leukocyte infusion (pDLI) to convert MC to full donor chimerism (FDC) and capture a graft-versus-tumor effect without clinical graft-versus-host disease (GVHD). Neutrophil and platelet recovery were faster and transfusion requirement was less in PBSC recipients (P<0.05). A total of 48% of BMT recipients achieved FDC with a median conversion time of 84 days, including 13 following pDLI. In contrast, 83% (P=0.04) in the PBSC group had spontaneous FDC at a median of 14 days, precluding the administration of pDLI. There was no significant difference in the incidences of acute or chronic GVHD, though the rates of chronic GVHD were considerably higher in PBSC group than in the BM group (6/7, 86% vs 10/24, 42%). CD4 and CD8 T-cell recovery was faster in PBSC recipients. In PBSC recipients, a higher number of CD34+ cells was associated with increased rates of severe, grade III–IV acute GVHD.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  1. Dreger P, Oberboster K, Schmitz N . PBPC grafts from healthy donors: analysis of CD34+ and CD3+ subpopulations. Bone Marrow Transplant 1996; 17 (Suppl 2): S22–S27.

    PubMed  Google Scholar 

  2. Pavletic ZS, Joshi SS, Pirruccello SJ, Tarantolo SR, Kollath J, Reed EC et al. Lymphocyte reconstitution after allogeneic blood stem cell transplantation for hematologic malignancies. Bone Marrow Transplant 1998; 21: 33–41.

    Article  CAS  Google Scholar 

  3. Champlin RE, Schmitz N, Horowitz MM, Chapuis B, Chopra R, Cornelissen JJ et al. Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. IBMTR Histocompatibility and Stem Cell Sources Working Committee and the European Group for Blood and Marrow Transplantation (EBMT). Blood 2000; 95: 3702–3709.

    CAS  PubMed  Google Scholar 

  4. Powles R, Mehta J, Kulkarni S, Treleaven J, Millar B, Marsden J et al. Allogeneic blood and bone-marrow stem-cell transplantation in haematological malignant diseases: a randomised trial. Lancet 2000; 355: 1231–1237.

    Article  CAS  Google Scholar 

  5. Blaise D, Kuentz M, Fortanier C, Bourhis JH, Milpied N, Sutton L et al. Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early-stage leukemia: a report from the Societe Francaise de Greffe de Moelle. J Clin Oncol 2000; 18: 537–546.

    Article  CAS  Google Scholar 

  6. Bensinger WI, Martin PJ, Storer B, Clift R, Forman SJ, Negrin R et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med 2001; 344: 175–181.

    CAS  PubMed  Google Scholar 

  7. Schmitz N, Beksac M, Hasenclever D, Bacigalupo A, Ruutu T, Nagler A et al. Transplantation of mobilized peripheral blood cells to HLA-identical siblings with standard-risk leukemia. Blood 2002; 100: 761–767.

    Article  CAS  Google Scholar 

  8. Couban S, Simpson DR, Barnett MJ, Bredeson C, Hubesch L, Howson-Jan K et al. A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies Canadian Bone Marrow Transplant Group. Blood 2002; 100: 1525–1531.

    Article  CAS  Google Scholar 

  9. Ringden O, Labopin M, Bacigalupo A, Arcese W, Schaefer UW, Willemze R et al. Transplantation of peripheral blood stem cells as compared with bone marrow from HLA-identical siblings in adult patients with acute myeloid leukemia and acute lymphoblastic leukemia. J Clin Oncol 2002; 20: 4655–4664.

    Article  CAS  Google Scholar 

  10. Tanimoto TE, Yamaguchi T, Tanaka Y, Saito A, Tajima K, Karasuno T et al. Comparative analysis of clinical outcomes after allogeneic bone marrow transplantation versus peripheral blood stem cell transplantation from a related donor in Japanese patients. Br J Haematol 2004; 125: 480–493.

    Article  Google Scholar 

  11. Scmitz N, Beksac M, Hasenclever D, Bacigalupo A, Ruutu T, Nagler A et al. A randomized study from European Group for Blood and Marrow Transplantation comparing allogeneic transplantation of filgrastim-mobilized peripheral blood progenitor cells with bone marrow transplantation in 350 patients with leukemia. Blood 2000; 96: 481a.

    Google Scholar 

  12. Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91: 756–763.

    CAS  Google Scholar 

  13. Khouri IF, Keating M, Korbling M, Przepiorka D, Anderlini P, O’Brien S et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 1998; 16: 2817–2824.

    Article  CAS  Google Scholar 

  14. Giralt S, Estey E, Albitar M, van Besien K, Rondon G, Anderlini P et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 1997; 89: 4531–4536.

    CAS  Google Scholar 

  15. Dey BR, McAfee S, Sackstein R, Colby C, Saidman S, Weymouth D et al. Successful allogeneic stem cell transplantation with nonmyeloablative conditioning in patients with relapsed hematologic malignancy following autologous stem cell transplantation. Biol Blood Marrow Transplant 2001; 7: 604–612.

    Article  CAS  Google Scholar 

  16. McSweeney PA, Niederwieser D, Shizuru JA, Sandmaier BM, Molina AJ, Maloney DG et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001; 97: 3390–4000.

    Article  CAS  Google Scholar 

  17. Khouri IF, Saliba RM, Giralt SA, Lee MS, Okoroji GJ, Hagemeister FB et al. Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood 2001; 98: 3595–3599.

    Article  CAS  Google Scholar 

  18. Sykes M, Szot GL, Swenson KA, Pearson DA . Induction of high levels of allogeneic hematopoietic reconstitution and donor-specific tolerance without myelosuppressive conditioning. Nat Med 1997; 3: 783–787.

    Article  CAS  Google Scholar 

  19. Pelot MR, Pearson DA, Swenson K, Zhao G, Sachs J, Yang YG et al. Lymphohematopoietic graft-vs-host reactions can be induced without graft-vs-host disease in murine mixed chimeras established with a cyclophosphamide-based nonmyeloablative conditioning regimen. Biol Blood Marrow Transplant 1999; 5: 133–143.

    Article  CAS  Google Scholar 

  20. Mapara MY, Yong-Mi K, Sheng-Ping W, Bronson R, Sachs DH, Sykes M . Donor lymphocyte infusions mediate superior graft-versus-leukemia effects in mixed compared to fully allogeneic chimeras: a critical role for host antigen-presenting cells. Blood 2002; 100: 1903–1909.

    Article  CAS  Google Scholar 

  21. Dey BR, McAfee S, Colby C, Sackstein R, Saidman S, Tarbell N et al. Impact of prophylactic donor leukocyte infusions on mixed chimerism, graft-vs-host disease, and anti-tumor response in patients with advanced hematologic malignancies treated with nonmyeloablative conditioning and allogeneic bone marrow transplantation. Biol Blood Marrow Transplant 2003; 9: 320–329.

    Article  Google Scholar 

  22. Vigorito AC, Azevedo WM, Marques JF, Azevedo AM, Eid KA, Aranha FJ et al. A randomised, prospective comparison of allogeneic bone marrow and peripheral blood progenitor cell transplantation in the treatment of haematological malignancies. Bone Marrow Transplant 1998; 22: 1145–1151.

    Article  CAS  Google Scholar 

  23. Heldal D, Tjonnfjord G, Brinch L, Albrechtsen D, Egeland T, Steen R et al. A randomised study of allogeneic transplantation with stem cells from blood or bone marrow. Bone Marrow Transplant 2000; 25: 1129–1136.

    Article  CAS  Google Scholar 

  24. Kraus AB, Shaffer J, Toh HC, Preffer F, Dombkowski D, Saidman S et al. Early host CD8 T-cell recovery and sensitized anti-donor interleukin-2-producing and cytotoxic T-cell responses associated with marrow graft rejection following nonmyeloablative allogeneic bone marrow transplantation. Exp Hematol 2003; 31: 609–621.

    Article  Google Scholar 

  25. Pan L, Delmonte Jr J, Jalonen CK, Ferrara JL . Pretreatment of donor mice with granulocyte colony-stimulating factor polarizes donor T lymphocytes toward type-2 cytokine production and reduces severity of experimental graft-versus-host disease. Blood 1995; 86: 4422–4429.

    CAS  PubMed  Google Scholar 

  26. Talmadge JE, Reed EC, Kessinger A, Kuszynski CA, Perry GA, Gordy CL et al. Immunologic attributes of cytokine mobilized peripheral blood stem cells and recovery following transplantation. Bone Marrow Transplant 1996; 17: 101–109.

    CAS  PubMed  Google Scholar 

  27. Arpinati M, Green CL, Heimfeld S, Heuser JE, Anasetti C . Granulocyte-colony stimulating factor mobilizes T helper 2-inducing dendritic cells. Blood 2000; 95: 2484–2490.

    CAS  PubMed  Google Scholar 

  28. Liu YJ, Blom B . Introduction: TH2-inducing DC2 for immunotherapy. Blood 2000; 95: 2482–2483.

    CAS  PubMed  Google Scholar 

  29. Sloand EM, Kim S, Maciejewski JP, Van Rhee F, Chaudhuri A, Barrett J et al. Pharmacologic doses of granulocyte colony-stimulating factor affect cytokine production by lymphocytes in vitro and in vivo. Blood 2000; 95: 2269–2274.

    CAS  PubMed  Google Scholar 

  30. Rutella S, Pierelli L, Bonanno G, Sica S, Ameglio F, Capoluongo E et al. Role for granulocyte colony-stimulating factor in the generation of human T regulatory type 1 cells. Blood 2002; 100: 2562–2571.

    Article  CAS  Google Scholar 

  31. Morris ES, MacDonald KP, Rowe V, Johnson DH, Banovic T, Clouston AD et al. Donor treatment with pegylated G-CSF augments the generation of IL-10-producing regulatory T cells and promotes transplantation tolerance. Blood 2004; 103: 3573–3581.

    Article  CAS  Google Scholar 

  32. Cutler C, Giri S, Jeyapalan S, Paniagua D, Viswanathan A, Antin JH . Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation: a meta-analysis. J Clin Oncol 2001; 19: 3685–3691.

    Article  CAS  Google Scholar 

  33. Storek J, Gooley T, Siadak M, Bensinger WI, Maloney DG, Chauncey TR et al. Allogeneic peripheral blood stem cell transplantation may be associated with a high risk of chronic graft-versus-host disease. Blood 1997; 90: 4705–4709.

    CAS  PubMed  Google Scholar 

  34. Przepiorka D, Smith TL, Folloder J, Khouri I, Ueno NT, Mehra R et al. Risk factors for acute graft-versus-host disease after allogeneic blood stem cell transplantation. Blood 1999; 94: 1465–1470.

    CAS  PubMed  Google Scholar 

  35. Martin PJ . The role of donor lymphoid cells in allogeneic marrow engraftment. Bone Marrow Transplant 1990; 6: 283–289.

    CAS  PubMed  Google Scholar 

  36. Mohty M, Gaugler B . Dendritic cells: interfaces with immunobiology and medicine. A report from the Keystone Symposia Meeting held in Keystone, 3-8 March 2003. Leukemia 2003; 17: 1753–1758.

    Article  CAS  Google Scholar 

  37. Urbano-Ispizua A, Carreras E, Marin P, Rovira M, Martinez C, Fernandez-Aviles F et al. Allogeneic transplantation of CD34(+) selected cells from peripheral blood from human leukocyte antigen-identical siblings: detrimental effect of a high number of donor CD34(+) cells? Blood 2001; 98: 2352–2357.

    Article  CAS  Google Scholar 

  38. Perez-Simon JA, Diez-Campelo M, Martino R, Sureda A, Caballero D, Canizo C et al. Impact of CD34+ cell dose on the outcome of patients undergoing reduced-intensity-conditioning allogeneic peripheral blood stem cell transplantation. Blood 2003; 102: 1108–1113.

    Article  CAS  Google Scholar 

  39. Ottinger HD, Beelen DW, Scheulen B, Schaefer UW, Grosse-Wilde H . Improved immune reconstitution after allotransplantation of peripheral blood stem cells instead of bone marrow. Blood 1996; 88: 2775–2779.

    CAS  Google Scholar 

  40. Storek J, Dawson MA, Storer B, Stevens-Ayers T, Maloney DG, Marr KA et al. Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantation. Blood 2001; 97: 3380–3389.

    Article  CAS  Google Scholar 

  41. Hellerstein M, Hanley MB, Cesar D, Siler S, Papageorgopoulos C, Wieder E et al. Directly measured kinetics of circulating T lymphocytes in normal and HIV-1-infected humans. Nat Med 1999; 5: 83–89.

    Article  CAS  Google Scholar 

  42. Mclean AR, Michie CA . In vivo estimates of division and death rates of human T lymphocytes. Proc Natl Acad Sci USA 1995; 92: 3707–3711.

    Article  CAS  Google Scholar 

  43. Michie CA, McLean A, Alcock C, Beverley PC . Lifespan of human lymphocyte subsets defined by CD45 isoforms. Nature 1992; 360: 264–265.

    Article  CAS  Google Scholar 

  44. van Rhee F, Jiang YZ, Vigue F, Kirby M, Mavroudis D, Hensel NF et al. Human G-CSF-mobilized CD34-positive peripheral blood progenitor cells can stimulate allogeneic T-cell responses: implications for graft rejection in mismatched transplantation. Br J Haematol 1999; 105: 1014–1024.

    Article  CAS  Google Scholar 

  45. Rondelli D, Raspadori D, Anasetti C, Bandini G, Re F, Arpinati M et al. Alloantigen presenting capacity, T cell alloreactivity and NK function of G-CSF-mobilized peripheral blood cells. Bone Marrow Transplant 1998; 22: 631–637.

    Article  CAS  Google Scholar 

  46. Ryncarz RE, Anasetti C . Expression of CD86 on human marrow CD34(+) cells identifies immunocompetent committed precursors of macrophages and dendritic cells. Blood 1998; 91: 3892–3900.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA

    B R Dey, J Shaffer, A J Yee, S McAfee, M Caron, K Power, D T Ting, C Colby, F Preffer, K Ballen, E Attar, S Saidman, N Tarbell, D Sachs, M Sykes & T R Spitzer

Authors
  1. B R Dey
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J Shaffer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A J Yee
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S McAfee
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M Caron
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. K Power
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. D T Ting
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. C Colby
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. F Preffer
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. K Ballen
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. E Attar
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. S Saidman
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. N Tarbell
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. D Sachs
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. M Sykes
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. T R Spitzer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C Colby.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dey, B., Shaffer, J., Yee, A. et al. Comparison of outcomes after transplantation of peripheral blood stem cells versus bone marrow following an identical nonmyeloablative conditioning regimen. Bone Marrow Transplant 40, 19–27 (2007). https://doi.org/10.1038/sj.bmt.1705688

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1705688

Keywords

This article is cited by

Search

Advanced search

Quick links